Ongoing research is also exploring their potential in non-oncologic diseases, such as autoimmune disorders, neurodegeneration (e.g., Alzheimer’s disease), and metabolic syndromes, suggesting a broader future impact of DNMT inhibition beyond cancer. The gene discussed is DNMT1; the disease is cancer.